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ABSTRACT
Despite the increasing wealth of available data, the
structure of cancer transcriptional space remains
largely unknown. Analysis of this space would
provide novel insights into the complexity of cancer,
assess relative implications in complex biological
processes and responses, evaluate the effective-
ness of cancer models and help uncover vital
facets of cancer biology not apparent from current
small-scale studies. We conducted a comprehen-
sive analysis of pancreatic cancer-expression space
by integrating data fromotherwise disparate studies.
We found (i) a clear separation of profiles based on
experimental type, with patient tissue samples, cell
lines and xenograft models forming distinct groups;
(ii) three subgroups within the normal samples adja-
cent to cancer showing disruptions to biofunctions
previously linked to cancer; and (iii) that ectopic
subcutaneous xenografts and cell line models do
not effectively represent changes occurring in pan-
creatic cancer. All findings are available from our
online resource for independent interrogation.
Currently, the most comprehensive analysis of pan-
creatic cancer to date, our study primarily serves to
highlight limitations inherent with a lack of raw data
availability, insufficient clinical/histopathological
information and ambiguous data processing. It
stresses the importance of a global-systems
approach to assess and maximise findings from ex-
pression profiling of malignant and non-malignant
diseases.
INTRODUCTION
Every cancer reﬂects the highly heterogeneous make-up of
the patient’s genes, the stochastic mutational processes
occurring within the tumour; the balance between these
processes ultimately determining each tumour’s unique
proﬁle (1,2). These inter-individual differences are evident
in the variability of patient outcome. Under intensive in-
vestigation for the past decade, a wealth of information is
now available on transcriptional regulation differences in
tumourigenesis across multiple histological cancer types,
cultured cells and xenograft models. Although critically
needed to maximise cancer research, the interconnections
between the molecular events that govern this transcrip-
tional space in cancer are still largely unknown since most
studies focus on molecular proﬁling a single sample type
or condition. The same is true for non-malignant diseases
where the amount of transcriptomic data obtained by mo-
lecular proﬁling a wide range of tissues and cells affected
by the disease has grown exponentially.
A global integrated analysis of gene expression data
generated by many different laboratories will reveal the
overall structure of gene-expression space while enhancing
the sensitivity of the analysis, by yielding improved statis-
tical power and novel biological insight. This helps conﬁ-
dently assess sources of variability in the data and remove
the poor-quality arrays that could compromise the statis-
tical and biological signiﬁcance of the original study (3).
There are two general approaches to comparative pro-
ﬁling analysis. The ﬁrst method requires normalising and
re-analysing the original data from each individual study.
A limited number of meta-analyses tend to rely on this
rigorous and reliable method because of problems asso-
ciated with cross-platform analyses and most importantly
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the availability of both raw data and clinical information.
The second approach is based on the assumption that es-
sential genes will be consistently altered and relies on the
identiﬁcation of intersections between studies. While inde-
pendent from the availability of raw data, this type of
meta-analysis depends heavily on the pre-processing and
analysis methods, the signiﬁcance threshold and the anno-
tation builds used in the original publication, not all of
which are always accurate and reproducible (4).
A recent study has used the ﬁrst method to produce a
global map of human gene expression derived from the
extensive analysis of 14 500 human genes across 5372
samples representing the structure of the expression space
of 369 different cell and tissue types, disease states and cell
lines (5). The authors showed that the major patterns are
attributable to the tissue of origin independent of the
disease state. Additional comparative analysis also deter-
mined that global patterns of tissue-speciﬁc expression of
orthologous genes are conserved between human and
mouse (6). The impact of such analyses on cancer research
is hampered not only by the uniqueness and complexity of
each cancer type but also by the quality and magnitude of
raw and clinical annotations of cancer samples inter-
rogated. In an attempt to assess and expand this global
map to cancer research, we have analysed pancreatic
cancer-speciﬁc expression data.
Pancreatic cancer is a major health problem and the
fourth most common cause of cancer-related death
world wide, with survival statistics relatively unchanged
over the past 30 years (7). A multitude of studies have
been dedicated to elucidating the pathogenesis of this
disease, resulting in the generation and publication of an
increasing volume of transcriptomics data (8). Hence,
there is no shortage of pancreatic cancer raw data but
an urgent need for robust and rigorous data analysis for
establishing whether the results are valid and accurate.
Unfortunately, relative to other malignancies, this is still
somewhat under-investigated in the ﬁeld of pancreatic
cancer.
By enabling essential data integration and analysis, this
is the ﬁrst study that will allow the international commu-
nity to assess and exploit the high volume of raw pancreatic-
cancer data to maximal advantage. As the amount of cancer
data continues to grow, this study is needed to evaluate
the quality of the data generated and address the impact of
molecular targets on cancer development, progression and
resistance to treatment. Importantly, public repositories
do not assess the quality of the deposited datasets or pro-
vide information on the data processing used. Therefore,
one still has to carefully review the experimental and
clinical annotations associated with the deposited raw
data ﬁles.
This study overcomes these challenges to permit in-
depth mining of different types of pancreatic cancer data.
Our group has a lead in this development by having suc-
cessfully established the Pancreatic Expression Database
(PED) to address these challenges in published literature
(9,10). PED is unique since it is the only tool currently
available for mining of curated pancreatic cancer-literature
data. This project is complementary but distinct from
PED. It aims to perform an upstream analysis starting
from the raw data in order to evaluate its quality and
perform an in-depth data analysis of the structural space
of pancreatic cancer expression data. All our ﬁndings will
be linked to the PED portal making it a one-stop solution
for the integration, analysis and visualisation of raw and
literature-derived pancreatic cancer data.
MATERIALS AND METHODS
Data collection
A total of 309 raw pancreatic cancer expression data ﬁles,
generated on the highly comprehensive Affymetrix
GeneChip Human Genome U133 Plus 2.0 array
(47 000 transcripts) were obtained from the Gene
Expression Omnibus (GEO) (11), Array Express (12)
and the expO project (https://expo.intgen.org/geo/home
.do). When the data were available from GEO and
ArrayExpress, the concordance was ascertained.
Additional normal pancreas sample data were obtained
from GEO and Affymetrix (www.affymetrix.com).
Data pre-processing
All processing was performed using Bioconductor packages
(www.bioconductor.org) within theR statistical environment
(www.r-project.org). The arrayMvout package was utilised
to implement stringent quality control criteria to the data-
sets. Nine quantitative features of array quality, computed
on each array, were evaluated: ABG (average back-
ground); SF (scale factor); PP (percent of present calls);
AR (actin 30/50ratio); GR (GAPDH 30/50 ratio); median
normalised unscaled standard error (NUSE); median
relative log expression (RLE); RLE-IQR (interquartile
range of IQR per array, to measure variability in RLE)
and RNAS (slope of RNA degradation measure). These
components were subsequently analysed using principal
components 1, 2 and 3 analysis, followed by parametric
multivariate outlier detection with calibration for multiple
testing. A false positive rate of 0.01 for outlier detection,
adjusting for multiple comparisons according to Caroni
and Prescott’s adaptation of Rosner was used (13,14).
All data ﬁles passing the quality control checks were sub-
sequently normalised jointly to create a global space of
gene expression in pancreatic cancer.
Data normalisation and dimensionality reduction
The primary data from all studies were normalised using
the GC-RMA hybrid algorithm with the GCRMA
package. This normalising method was selected because,
while being based on the Robust Multi-array Average
(RMA) algorithm, it also accounts for GC-content back-
ground correction. Furthermore, GC-RMA has recently
been recommended for the detection of differentially ex-
pressed genes (15,16). The probe sets were ﬁltered using
standard deviation calls to isolate a list of the top 10 000
most variable probe sets across all experiments.
Differential expression analysis
Genes differentially regulated between biological groups
were identiﬁed using limma (17). We applied an
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unbiased linear model and estimated the variance across
the whole panel of samples so all comparisons have the
same power. We used the duplicate correlation method
from limma to adjust for replicates. The Benjamini and
Hochberg (BH) false discovery rate (FDR) was used for
multiple testing corrections. A double cut-off of
FDR 0.01 and a fold change of 2 were set for the dis-
covery analysis. Further, more stringent, thresholds of
FDR 0.005 and fold changes of 2, 3 and 4 were also
used to narrow down the list of deregulated genes and
highlight the most affected pathways. We validated the
differential pattern of expression for the biological com-
parisons taking into account within-group correlation, by
treating study group as a random effect in a mixed effects
model. Subsequently, Venn diagrams with four groups
were generated by using an extension on the code from
the limma package, available from http://bioinfo-mite.crb
.wsu.edu/Rcode/Venn.R.
Principle component analysis and hierarchical clustering
PCA, using the R stats package, was applied, thereby
reducing the dimensionality of the data to identify key
components of variability. The R package pcaMethods
was used to evaluate the cross-validation of our PCA
model with the explained variance coefﬁcients Q2 and
R2, respectively. Moreover, as an internal validation, we
have randomly removed 10% of the data to ensure the
cluster tree was not affected. The cluster Bioconductor
package was used for extended analysis, providing an incr-
eased insight of interactions via subgrouping of normal-
adjacent expression data. Using the A2R package,
unsupervised clustering, based on the Euclidean distance
matrix and the average linkage algorithm, was performed.
Pathway analysis
Ingenuity Pathway Analysis (www.ingenuity.com), version
8.5, was used as a means to interrogate the data and
identify various pathways and biofunctions deregulated
within the different samples.
Accessibility of the data
An independent online resource has been constructed and
implemented for the exploration of our ﬁndings. This
user-friendly interface will enable researchers to query
for a given gene(s) or probe(s); biological function(s)
and canonical pathway(s); and then visualise the expres-
sion and differential expression levels across each of the
sample types.
RESULTS
Sample selection
We collected pancreatic-related expression data ﬁles from
public repositories. These included 309 samples (18–28)
comprising of: four normal pancreas (commercial source);
55 normal-adjacent pancreas (pancreatic cancer patients);
96 pancreatic cancer [pancreatic cancer patients, repre-
senting 91 pancreatic ductal adenocarcinoma (PDAC)
and ﬁve other pancreatic cancer types]; 65 pancreatic
cancer cell lines (29 distinct cell lines); 24 saliva specimens
(12 healthy subjects and 12 pancreatic cancer patients); 59
ectopic subcutaneous xenografts (pancreatic cancer pa-
tients) and six orthotopic xenografts (pancreatic cancer cell
lines) (Supplementary Table S1). A total of 51 arrays,
identiﬁed as outliers in quality control checks, were
excluded from additional analyses. These included all the
proﬁles representing saliva, three pancreatic cancer cell
lines (Capan1, HPAC, SW1990), orthotopic xenografts
from L3.6pl cell line and non-functional islet cell tumour
(Supplementary Table S1). In addition, one of the raw ex-
pression ﬁles was corrupted (23) and hence also removed.
Normalisation and statistical analyses were performed on
the remaining data ﬁles.
Initial clustering analysis
PCA generated to view the underlying structure of the
data showed two axes; microenvironment and malig-
nancy, with patient tissue samples, xenograft models and
cultured cell lines located in separate areas of the ﬁrst
empirical principal component and samples dispersed on
the second empirical principal component based on their
tumour content (Figure 1, Supplementary Figures S1
and S2). We found that the ﬁrst two principal components
explain 42% of variability and have biological interpret-
ations. Cross-validation showed that we do not appear
to be overﬁtting the data by using two components.
Unsupervised HCL yielded similar results, highlighting
two predominant groups (Supplementary Figure S3).
The ﬁrst group comprised normal and cancer samples;
and the second group consisted of xenograft models and
cell lines. In accordance with the PCA, the clustering pro-
ﬁles from normal pancreatic tissue resected adjacent to
cancer were found interspersed between normal donors
(ND) and pancreatic cancer samples. Prior to conducting
further analysis, PCA of sample origin was conducted
to ascertain the premise that the biological effects were
stronger than any laboratory inﬂuences (Supplementary
Figure S4). Since the study groups are effectively nested
within the microenvironment factor, estimating the
relative effect sizes is not achievable. However, the clus-
tering of the samples, resulting in study groups targeting
the same microenvironments tending to cluster together,
and then within samples from the same study group clus-
tering, indicates that the biological factors are the primary
effect. Further inspection of average similarities between
samples from different studies but within the same bio-
logical group and samples from the same study but repre-
senting different biological groups showed that the
biological effects were signiﬁcantly stronger than the study
effects (P< 2.216) (Supplementary Figure S5). For bio-
logical groups to which only one study contributed, we
cannot distinguish directly between the study and bio-
logical effects.
Biological interpretations from in-depth statistical analyses
Closer inspection of proﬁles from histologically ‘normal-
appearing’ tissue adjacent to pancreatic cancer indicated
the presence of three distinct subgroups (NAD1, NAD2
and NAD3) (Figure 2 and Supplementary Figure S6).
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The ﬁrst subgroup comprises of ND and the normal-
adjacent samples whose proﬁles most closely resemble
those of ND. Sample proﬁles in the second group (NAD2)
are sufﬁciently different to NAD1 to form a distinct sub-
group. The third subgroup (NAD3) reﬂects the expression
proﬁles of samples most closely resembling those of
PDAC. Additional analyses were implemented in an
attempt to characterise this heterogeneity.
To this end, the PDAC group and each normal-adjacent
subgroup were initially compared against normal tissues
from healthy donors. By making this direct comparison
against normal pancreatic tissues, we took advantage of a
‘subtractive’ effect, which emphasised genes that consist-
ently distinguished normal, normal-adjacent and cancer
tissues. Subsequently, the common and unique genes identi-
ﬁed as deregulated in PDAC and each normal-adjacent
subgroup were assessed (Supplementary Figure S7). This
circumvents issues with a lack of statistical power in other
conventional disparate-study analyses with lower sample
numbers, to identify a set of genes that deﬁne a molecular
signature capable of distinguishing benign tissue resected
adjacent to cancer from malignant tissue.
The top genes differentially expressed in each of the
normal-adjacent subgroups and PDAC were selected and
pathway analyses conducted. Three predominant groups
of biofunctions were detected profoundly affected between
all the normal subgroups and PDAC (Supplementary
Figure S8). These pathways include: cancer-speciﬁc bio-
processes, such as deregulation in the apoptotic pathways,
aberrant cellular growth, proliferation and development
and disruption to cell cycle regulation; moieties involved
in the inﬂammatory response pathways and other im-
munological responses; and an array of metabolic path-
ways, predominantly those involved in lipid metabolism,
metabolic disease and vitamin and mineral metabolism.
Each of these biofunctions have previously been linked
to tumourigenesis (29–32)
Further comparisons of the signalling pathways and
processes found altered in the ‘normal-appearing’
samples to those previously reported to be altered in pan-
creatic cancer generated an unexpected amount of overlap
(Supplementary Table S2) (31). This suggests that varying
similarities exist in the pathways deregulated between each
of the normal-adjacent subgroups and PDAC.
To ensure a thorough examination of all the pancreatic-
cancer data available, attempts were made to investigate
whether genetic alterations associated with pancreatic
cancer were preserved and reﬂected in a similar manner
by the xenotransplanted samples and the cell lines. Since
the aim of this study was to use available raw data to
PC1
PC
2
Cell lines
Healthy donors
Normal−adjacent
Other pancreatic cancer
PDAC
Xenograft
Figure 1. PCA plot of the global structure of pancreatic cancer-transcriptional space. The two main principle components can be visualised in this
PCA. Each point represents the orientation of a single sample in a multi-dimensional gene expression space projected on the PCA, with different
colours illustrating the biological group to which each sample belongs. The samples can be divided into three areas: xenograft models (yellow);
cell-line models (purple) and human-derived proﬁles (green, red, black and blue).
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evaluate the global structure of the transcriptional space
of a cancer-speciﬁc environment across its different sam-
ples and models, conﬁrming or disproving the original
ﬁndings was not our intention and should not be taken
as evidence that the published analyses are wrong.
The xenograft models were found to have a greater simi-
larity to cell lines than to PDAC, suggesting that these
models are unable to truly represent alterations occurring
in pancreatic tumours (Figure 1). Differential expression
relating to the effect of various drugs and treatments on
ectopic xenografts and pancreatic cancer cell lines were
also investigated. Although we were not able to fully rep-
licate the results at the gene level, our overall ﬁndings were,
to a certain extent, in concordance with the reported
ﬁndings at the pathway level.
Attempts were made to identify key biological charac-
teristics, which could account for any variability or simi-
larities between the different cell lines: AsPC1, YPAC,
HuPT4 and MiaPaCa2 (well-characterised pancreatic-
cancer cell lines with at least three replicates available)
(Supplementary Figure S9). Overall, the cell lines sepa-
rated according to phenotypic characteristics, with some
effect being exerted based on the origin of the cell line
(Supplementary Figure S10). Pathway analysis on the
four, aforementioned, cell lines appeared to support this,
with invasion- and metastasis-associated pathways and
molecules being deregulated to a greater extent in the
more aggressive cell lines. An interesting observation was
that the MiaPaCa2 cell line appears to be unique in its
own right. The expression proﬁles of this cell line, obtained
from multiple studies and exposed to different treatments,
remained consistently distinct from all other pancreatic
cancer cell lines. As before, the risk of bias from individual
studies was assessed, with the biological effects being
greater than any laboratory effects (Supplementary
Figure S11).
Portal for data-mining
The web portal (http://www.pancreasexpression.org/
PancreaticCancerLandscape.html) accompanying this art-
icle was developed as an accompanying tool to add conﬁ-
dence to gene-expression queries made using PED. In
addition to allowing a rapid querying of pre-processed
analyses of the data for all the well-represented deﬁned
subtypes, it also offers visualisation of the expression
boxplots and heatmaps. At present, the four primary
modes for querying these analyses are by: gene/probe,
comparison, biological function and pathway.
Similarly to PED, scientists are able both to follow their
gene of interest and mine for additional genes, thereby faci-
litating the design of validation experiments. In addition,
they are also able to observe the pathways to which
these genes are linked. This increased dimensionality to
PED queries will facilitate novel ﬁndings and conclusions.
DISCUSSION
Our study encompasses the largest number of pancreatic-
cancer proﬁles generated on a high-resolution expression
array thereby ensuring that this is the most comprehensive
analytical analysis of pancreatic cancer to date. By sub-
jecting all the datasets from all the studies to the same
rigorous quality control criteria and treating them jointly
to a single, well-annotated, data processing pipeline, we
have eliminated any differences in results attributable to
analytical diversity. Furthermore, the increased statistical
power and the capacity to generate comparisons not avail-
able from the disparate studies increase the ability to pro-
vide novel insights. This robust integrative analysis of
multiple and diverse pancreatic cancer datasets has high-
lighted some important ﬁndings and issues.
Our main ﬁnding suggests that normal tissues, often
used as a baseline against which cancer proﬁles are com-
pared, may have already acquired a number of genetic
alterations. This is of relevance not only in highlighting
the possibility of ‘ﬁeld change’ in cancer, and the genes
that characterise this, but importantly, that the ‘normal’
matched samples in many studies may not be an appro-
priate baseline for comparison with cancers. This may par-
tially contribute to the lack of reproducibility between
studies. We also show distinctions between proﬁles gene-
rated by studies based on cell lines and cell line-derived
models to those using tumour samples. The ectopic sub-
cutaneous xenograft models do not appear capable of ac-
curately representing tumour behaviour, instead sharing
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These two components explain 90.96 % of the point variability.
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Figure 2. Bivariate clustering of the normal and normal-adjacent ex-
pression proﬁles. The emergence of three distinct subgroups, NAD1,
NAD2 and NAD3, respectively, can be noted. The ﬁrst subgroup (blue
and red circles) comprises of ND and the normal-adjacent samples
whose proﬁles most closely resemble those of ND (NAD1). Sample
proﬁles in NAD2 (green triangles) are sufﬁciently different to NAD1
to form a distinct subgroup. The third subgroup (NAD3) reﬂects the
expression proﬁles of samples most closely resembling those of PDAC
(dark blue crosses).
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greater similarities with pancreatic cancer cell lines (33).
Furthermore, our observations, especially those relating
the MiaPaCa2 cell lines, suggest that it is important for
the research community to examine the origins and
properties of cancer cell lines prior to use, thereby
ensuring optimal recapitulation of the characteristics of
the cancer being investigated.
Initially conducted to provide an insight to the molecu-
lar events governing the transcriptional space of pancre-
atic cancer, this study serves to highlight concerns with the
availability and quality of publicly accessible gene expres-
sion data. The main issue encountered was the lack of
sufﬁcient clinical and histopathological information avail-
able in the public domain, all of which act as a barrier to
the accurate interpretation of cancer expression data.
Similarly, a lack of detailed experimental and analytical
documentation also hampers conclusive data evaluation
and reproducibility. Attempts to overcome some of these
limitations by obtaining access to additional clinical data
were not met with success, precluding further investigation
in the majority of cases. Heterogeneity of information cur-
rently available to the pancreatic cancer community
means that, while our ﬁndings are interesting, without
additional documentation regarding these samples,
accurate evaluations of the data are not possible.
Our study shows the limitations that lack of complete
good quality data can have on interpretation of results.
First, in order to fully determine whether the seemingly
normal-adjacent tissues have undergone alteration when
compared to tissues obtained from ND, this study would
have needed to analyse tissue selected to ensure similar
tissue composition and exclude areas of inﬂammation
and ﬁbrosis. Unfortunately, chronic pancreatitis data
proﬁled on the same platform were not available in
public repositories for a direct comparison of expression
signatures. This would have enabled considerably more
reliable evidence for or against a ‘cancer ﬁeld effect’ hy-
pothesis in the normal-adjacent subgroup. Furthermore,
information on the distance of the margins of resection
along with additional histopathological data was not
provided in the majority of studies used in this analysis.
Lack of standardisation of histopathological examinations
have recently been shown to inﬂuence the reporting of
resection margin status (34). Therefore, it is possible that
some of our observations are attributable to a contamin-
ation artefact with differing degrees of cancer cell inﬁltra-
tion within samples utilised as normal.
Increased conﬁdence to our second observation, that
ectopic subcutaneous xenograft and cell-line models do
not appear to represent tumour behaviour in vivo, could
be attained by ensuring that proﬁles obtained using the
same sampling procedures are used for comparison. In
this instance, use of bulk tissues, containing not only
cancer cells but also stromal cells, from primary tumour
samples was compared to high-cellularity pancreatic-
carcinoma proﬁles from the xenograft models. Thus, it is
possible that some of the observations could be attributed
to differences in contaminating stromal cells. In addition,
some of the differences in gene expression could be
attributed to the contribution of desmoplastic stroma, of
which pancreatic tumours tend to have a large proportion,
which is not reproduced in cell line and xenograft models
(35). This hypothesis could be either supported or dis-
proved by a comparison of primary tissue proﬁles with
micro-dissected proﬁles, in which desired cells are isolated
from the xenograft specimens from the same tumour.
Unfortunately, the low quality of the tissues available
for this meta-analysis did not allow for this comparison
to be generated.
To further enhance transparency and avoid publication
and/or author bias, all our ﬁndings have been made pub-
licly available in an online tool. Designed to complement
PED queries, this tool will enable the pancreatic cancer
research community to interrogate and compare results
from the two main comparative analysis approaches; lit-
erature analysis and re-analysis of raw data. Integration of
the two types of results will increase the utility of both
resources and will help address issues associated with pub-
lication bias.
We have shown that data founded on poor quality as-
surance and insufﬁcient documentation provision and uni-
formity is problematic to re-analyse, restricting the
evaluative capabilities of our aggregate analysis, these
limitations have also proven dangerous in the clinical en-
vironment (36). Moreover, research that bases ﬁndings
predominantly on the results of a small number of indi-
vidual studies, for which detailed documentation is
missing, will contain any errors made in the original
studies.
So, while integrative global analyses are capable of
providing a wealth of valuable data and insights unachiev-
able from single studies, the poor information on sample
histology (linked to the raw data available in public data-
bases) makes it difﬁcult to interpret, with conﬁdence,
any results towards new biological insight. Our study
adds to the proof that incomplete information on tissue
composition and/or the use of well-deﬁned tissues se-
verely hampers any meaningful data analysis and conclu-
sive data interpretation. This problem seems to be
prominent in a disease as complex as pancreatic cancer,
known for its confounding characteristics such as poor
cellularity; high-stromal reaction; accompanying pancrea-
titis; and various tumour-associated inﬂammatory cells.
Due to the plasticity of pancreatic cells and reports of
multiple cell types being potential precursor cells, it
remains an open question whether the relevant normal
cells to be used as a baseline for comparison to ductal
pancreatic cancer are normal ductal cells or acinar cells.
The data from pancreatic cancer and normal-adjacent
tissues available for this study in public repositories rely
on studies using whole tissues with no attached informa-
tion on histological quality criteria. Thus, the criteria used
to deﬁne normal-adjacent tissues are unclear from these
studies.
For most journals, submitting raw data to public repos-
itories is mandatory. However, while public repositories
verify the ﬁle format, the quality of clinical and raw data is
not assessed. It is vital that both original submitters and
public repositories ensure that good quality raw data in
conjunction with full histological and clinical data, detailed
experimental design and unambiguous analysis pipelines
are made publicly available. Without addressing these
Nucleic Acids Research, 2011, Vol. 39, No. 18 7905
obstacles, the increasing abundance of any disease data
becoming available cannot be used to its maximal
potential.
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